EUVIMEDEUVIMED entdecken
Crossref

Novel genomic risk stratification model for primary high‐grade malignant peripheral nerve sheath tumor ( MPNST )

Hsin-Yi Chang iD, Josephine K Dermawan iD, William Tap, Samuel Singer, Ping Chi, Cristina R Antonescu iD

The Journal of Pathology · 2026

DOI: 10.1002/path.70051 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Pathology, 2026. Verfasst von Hsin-Yi Chang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Biomarkers, Tumor, Neurofibrosarcoma. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: NIH HHS, Cycle for Survival, Kristin Ann Carr Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Risk stratification across the three main clinical subsets of malignant peripheral nerve sheath tumor (MPNST), neurofibromatosis type I (NF1‐related), sporadic, and prior radiation therapy (RT), is based mainly on clinicopathologic parameters, such as size, grade, stage, and NF1 status. Moreover, no prior study investigated the additional impact of genomic alterations in the prognosis of high‐grade MPNST using clinically validated DNA targeted next‐generation sequencing (NGS) panels. Our goal was to integrate clinicopathologic and genomic parameters using an elastic‐net penalized Cox proportional hazards machine learning model using OncoCast for risk prediction. Herein we perform comprehensive mutational and copy number profiling using Memorial Sloan Kettering–Integrated Mutation Profiling of Actionable Cancer Targets (MSK‐IMPACT) on 81 primary localized high‐grade MPNSTs (51% NF1‐related, 38% sporadic, 11% RT‐associated). The most common genomic alterations included NF1 (51% germline, 59% somatic), CDKN2A/B (62%), PRC2 components ( SUZ12 , EED ) (53%), and TP53 (25%). Variables selected by OncoCast as significantly associated with survival were used to construct a three‐tier risk stratification model for progression‐free survival (PFS) and disease‐specific survival (DSS). For PFS, patients with chr16 deletion were classified as high‐risk, those with concurrent germline and somatic NF1 alterations as low‐risk, and the remainder was assigned to the intermediate‐risk group. For DSS, cases with fraction genome altered (FGA) > 50% were defined as high‐risk, those with PRC2 abnormalities, CDKN2A deletion, TERT promoter mutation, or chr16 deletion as intermediate‐risk, and cases lacking all the aforementioned alterations as low‐risk. The high‐risk group showed significantly inferior survival compared to the low‐risk group (both PFS and DSS p < 0.001). Subgroup analysis showed that among NF1‐related MPNST, co‐occurring somatic NF1 mutation or WT TP53 was associated with superior PFS. Collectively, genomic alterations detected by clinical NGS panels provide potential new biomarkers for risk stratification that can be integrated with conventional parameters to provide improved prognostication and guide therapeutic strategies. © 2026 The Pathological Society of Great Britain and Ireland.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biomarkers, TumorNeurofibrosarcomaHumansFemaleRisk AssessmentMaleMutationMiddle AgedAdultRisk FactorsAgedGenetic Predisposition to DiseaseDNA Copy Number VariationsGenomicsYoung AdultNeoplasm Grading

Stichwörter der Autor:innen

CDKN2A/BNF1PRC2TP53genomic risk stratification modelmalignant peripheral nerve sheath tumor

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Pathology and Laboratory Medicine, Cleveland Clinic, Cleveland, OH, USA.
  • Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Human Oncology Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Hsin-Yi Chang, Josephine K Dermawan, Cristina R Antonescu

Förderung

  • NIH HHS
  • Cycle for Survival
  • Kristin Ann Carr Foundation
  • Yin Shu-Tien Foundation
  • Taipei Veterans General Hospital
  • National Yang Ming Chiao Tung University
  • National Institutes of Health

Zitieren

APA

Chang, H. Y., Dermawan, J. K., Tap, W., Singer, S., Chi, P., & Antonescu, C. R. (2026). Novel genomic risk stratification model for primary high‐grade malignant peripheral nerve sheath tumor ( MPNST ). The Journal of Pathology. https://doi.org/10.1002/path.70051

Vancouver

Chang HY, Dermawan JK, Tap W, Singer S, Chi P, Antonescu CR. Novel genomic risk stratification model for primary high‐grade malignant peripheral nerve sheath tumor ( MPNST ). The Journal of Pathology. 2026. doi:10.1002/path.70051

BibTeX
@article{Chang2026,
  author = {Chang, Hsin-Yi and Dermawan, Josephine K and Tap, William and Singer, Samuel and Chi, Ping and Antonescu, Cristina R},
  title = {Novel genomic risk stratification model for primary high‐grade malignant peripheral nerve sheath tumor ( MPNST )},
  journal = {The Journal of Pathology},
  year = {2026},
  doi = {10.1002/path.70051}
}
Kostenlos starten →